Abstract:In the development of cancer vaccines, antigens are delivered to elicit potent and specific T-cell responses to eradicate tumour cells. Nonetheless, successful vaccines are often hampered by the poor immunogenicity of tumour antigens, rapid clearance by the innate immunity, and limited cross-presentation on MHC-I to activate CD8 + T-cells arm. To address these issues, we developed dextran-based nanogels to promote antigen uptake, storage, and cross-presentation on MHC-I, while directing immunogenic maturation of the antigen-presenting cells (APCs). To promote the nanocarriers interaction with cells, we modified DX with L -arginine (Arg), whose immunomodulatory activities have been well documented. The ArgDX nanogel performance was compared with the nanogel modified with L -histidine (His) and L -glutamate (Glut). Moreover, we introduced pH-sensitive hydrazone crosslinking during the nanogel formation for the conjugation and controlled release of antigen ovalbumin (OVA). The OVA-laden nanogels have an average size of 325 nm. We demonstrated that the nanogels could rapidly release cargoes upon a pH change from 7 to 5 within 8 days, indicating the controlled release of antigens in the acidic cellular compartments upon internalization. Our results revealed that the ArgDX nanogel could promote greater antigen uptake and storage in DCs in vitro and promoted a stronger immunogenic maturation of DCs and M1 polarization of the macrophages. The OVA signals were co-localized with lysosomal compartments up till 96 hours post-treatment and washing, suggesting the nanogels could facilitate prolonged antigen storage and supply from endo-lysosomal compartments. Furthermore, all the tested nanogel formulations retained antigens at the skin injection sites until day 21. Such delayed clearance could be due to the formation of micron-sized aggregates of OVA-laden nanogels, extending the interactions with the resident DCs. Amongst the amino acid modifications, ArgDX nanogels promoted the highest level of lymph node homing signal CCR7 on DCs. The nanogels also showed higher antigen presentation on both MHC-I and II than DX in vitro . In the in vivo immune studies, ArgDX nanogels were more superior in inducing cellular and humoral immunity than the other treatment groups on day 21 post-treatment. These results suggested that ArgDX nanogel is a promising self-adjuvanted nanocarrier for vaccine delivery.

Antigen-loaded Nanocarriers Enhance the Migration of Stimulated Langerhans Cells to Draining Lymph Nodes and Induce Effective Transcutaneous Immunization

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Effective Transcutaneous Immunization by Antigen-Loaded Flexible Liposome in Vivo

Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization

Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines

Ovalbumin and Poly(i:c) Encapsulated Dendritic Cell‐Targeted Nanoparticles for Immune Activation in the Small Intestinal Lymphatic System

Differences in the distribution of stroke subtypes in a UK black stroke population – final results from the South London Ethnicity and Stroke Study

Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens

In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy

Enhanced Cancer Vaccination by In Situ Nanomicelle-Generating Dissolving Microneedles

Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination

β-glucan-modified nanoparticles with different particle sizes exhibit different lymphatic targeting efficiencies and adjuvant effects

Ph-Responsive Biomimetic Polymeric Micelles As Lymph Node-Targeting Vaccines for Enhanced Antitumor Immune Responses.

Tumor-draining Lymph Node Targeting Chitosan Micelles As Antigen-Capturing Adjuvants for Personalized Immunotherapy.

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

Iontophoresis‐Driven Microneedle Arrays Delivering Transgenic Outer Membrane Vesicles in Program That Stimulates Transcutaneous Vaccination for Cancer Immunotherapy

Microneedle-based two-step transdermal delivery of Langerhans cell-targeting immunoliposomes induces a Th1-biased immune response

Self-adjuvanted l-arginine-modified dextran-based nanogels for sustained local antigenic protein delivery to antigen-presenting cells and enhanced cellular and humoral immune responses

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8 + T Cell Responses

Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy

Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response